BYSI Latest Press Releases

-- April 22, 2026 --

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs Globe Newswire 7:00 AM

-- March 30, 2026 --

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 Globe Newswire 7:30 AM

-- March 25, 2026 --

BeyondSpring Files 2025 Annual Report on Form 10-K Globe Newswire 4:30 PM

BeyondSpring Reports 2025 Year-End Financial Results Globe Newswire 8:30 AM

-- February 9, 2026 --

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360 Conference Globe Newswire 7:15 AM

-- December 12, 2025 --

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path Globe Newswire 7:00 AM

-- December 11, 2025 --

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software